Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient ...
Add a second biologic or JAK1 inhibitor to biologic monotherapyAvoid adding an IL-1 inhibitor, which could raise infection risk ...
Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...
A new study published in the recent issue of Eye journal revealed that among patients with psoriasis, use of biologic drugs ...
Antibiotic exposure in psoriasis patients is linked to increased biologic therapy discontinuation, with risk rising with multiple courses, suggesting gut microbiota alterations may play a role. The ...
Early initiation of biologic therapy in patients with Crohn’s disease (CD) is associated with higher rates of transmural healing and leads to improved long-term outcomes. In CD, early initiation of ...
Medicare coverage for biologic therapies -- a mainstay of treatment for rheumatoid arthritis-- has been in flux recently. Medicare Part B coverage for biologic therapy ended in 2004, and the Medicare ...
It is the first clinical trial to evaluate a biologic therapy to prevent serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 ...
Biologic therapy within a year of diagnosis could decrease risk for disease progression among patients with ulcerative ...
Share on Pinterest Scientists may have found a way to predict which biologics may work best for people with rheumatoid arthritis. Westend61/Getty Images Rheumatoid arthritis is a painful, progressive ...
The SEAVUE study is the first head-to-head trial that compares the safety and efficacy of prescription biologics in the treatment of Crohn's disease, and results were presented during the 2021 ...
For patients with moderate to severe eosinophilic asthma or oral corticosteroid (OCS)-dependent asthma and inadequate disease control, the decision to add biologic therapy is based on the patient’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results